|
1
|
Isayeva T, Li Y, Maswahu D and
Brandwein-Gensler M: Human papillomavirus in non-oropharyngeal head
and neck cancers: A systematic literature review. Head Neck Pathol.
6 Suppl 1:S104–S120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lo KW, To KF and Huang DP: Focus on
nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheung F, Chan O, Ng WT, Chan L, Lee A and
Pang SW: The prognostic value of histological typing in
nasopharyngeal carcinoma. Oral Oncol. 48:429–433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spratt DE and Lee N: Current and emerging
treatment options for nasopharyngeal carcinoma. Onco Targets Ther.
5:297–308. 2012.PubMed/NCBI
|
|
5
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK,
Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and
Ensley JF: Chemoradiotherapy versus radiotherapy in patients with
advanced nasopharyngeal cancer: Phase III randomized Intergroup
study 0099. J Clin Oncol. 16:1310–1317. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee AW, Lau WH, Tung SY, Chua DT, Chappell
R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, et al: Preliminary
results of a randomized study on therapeutic gain by concurrent
chemotherapy for regionally-advanced nasopharyngeal carcinoma:
NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
J Clin Oncol. 23:6966–6975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wee J, Tan EH, Tai BC, Wong HB, Leong SS,
Tan T, Chua ET, Yang E, Lee KM, Fong KW, et al: Randomized trial of
radiotherapy versus concurrent chemoradiotherapy followed by
adjuvant chemotherapy in patients with American Joint Committee on
Cancer/International Union against cancer stage III and IV
nasopharyngeal cancer of the endemic variety. J Clin Oncol.
23:6730–6738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blanchard P, Lee A, Marguet S, Leclercq J,
Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, et al:
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An
update of the MAC-NPC meta-analysis. Lancet Oncol. 16:645–655.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Q, Fan H, Liu Y, Yin Z, Cai H, Liu J,
Wang Z, Shao M, Sun X, Diao J, et al: Curcumin enhances the
radiosensitivity in nasopharyngeal carcinoma cells involving the
reversal of differentially expressed long non-coding RNAs. Int J
Oncol. 44:858–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen JJ, Liu SX, Chen MZ and Zhao ZY:
Has-miR-125a and 125b are induced by treatment with cisplatin in
nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent
manner by targeting p53 mRNA. Mol Med Rep. 12:3569–3574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: Models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen YA, Wang CY, Hsieh YT, Chen YJ and
Wei YH: Metabolic reprogramming orchestrates cancer stem cell
properties in nasopharyngeal carcinoma. Cell Cycle. 14:86–98. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mueller MT, Hermann PC and Heeschen C:
Cancer stem cells as new therapeutic target to prevent tumour
progression and metastasis. Front Biosci (Elite Ed). 2:602–613.
2010.PubMed/NCBI
|
|
15
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kakarala M and Wicha MS: Cancer stem
cells: Implications for cancer treatment and prevention. Cancer J.
13:271–275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mannelli G and Gallo O: Cancer stem cells
hypothesis and stem cells in head and neck cancers. Cancer Treat
Rev. 38:515–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levine AJ and Oren M: The first 30 years
of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nii T, Marumoto T and Tani K: Roles of p53
in various biological aspects of hematopoietic stem cells. J Biomed
Biotechnol. 2012:9034352012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon DS, Choi Y and Lee JW: Cellular
localization of NRF2 determines the self-renewal and osteogenic
differentiation potential of human MSCs via the p53-SIRT1 axis.
Cell Death Dis. 11:e20932016. View Article : Google Scholar
|
|
22
|
Olivos DJ and Mayo LD: Emerging
non-canonical functions and regulation by p53: p53 and stemness.
Int J Mol Sci. 17(pii): E19822016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hegde S, Hankey P and Paulson RF:
Self-renewal of leukemia stem cells in friend virus-induced
erythroleukemia requires proviral insertional activation of Spi1
and hedgehog signaling but not mutation of p53. Stem Cells.
30:121–130. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of MiR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cowden Dahl KD, Dahl R, Kruichak JN and
Hudson LG: The epidermal growth factor receptor responsive miR-125a
represses mesenchymal morphology in ovarian cancer cells.
Neoplasia. 11:1208–1215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li W, Duan R, Kooy F, Sherman SL, Zhou W
and Jin P: Germline mutation of microRNA-125a is associated with
breast cancer. J Med Genet. 46:358–360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shang H, Wang T, Shang F, Huang KM and Li
YQ: A germline mutation in the miR-125a coding region reduces
miR-125a expression and is associated with human gastric cancer.
Mol Med Rep. 10:1839–1844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y, Huang Z and Liu Y: Reduced
miR-125a-5p expression is associated with gastric carcinogenesis
through the targeting of E2F3. Mol Med Rep. 10:2601–2608. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murakami Y, Yasuda T, Saigo K, Urashima T,
Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Gao JS, Tang X, Tucker LD,
Quesenberry P, Rigoutsos I and Ramratnam B: MicroRNA 125a and its
regulation of the p53 tumor suppressor gene. FEBS Lett.
583:3725–3730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao W, Chan JY and Wong TS: Curcumin
exerts inhibitory effects on undifferentiated nasopharyngeal
carcinoma by inhibiting the expression of miR-125a-5p. Clin Sci
(Lond). 127:571–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alzrigat M and Jernberg-Wiklund H: The
miR-125a and miR-320c are potential tumor suppressor microRNAs
epigenetically silenced by the polycomb repressive complex 2 in
multiple myeloma. RNA Dis. 4(pii): e15292017.PubMed/NCBI
|
|
36
|
Prabhu VV, Allen JE, Hong B, Zhang S,
Cheng H and El-Deiry WS: Therapeutic targeting of the p53 pathway
in cancer stem cells. Expert Opin Ther Targets. 16:1161–1174. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ginestier C, Charafe-Jauffret E and
Birnbaum D: p53 and cancer stem cells: The mevalonate connexion.
Cell Cycle. 11:2583–2584. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hong H, Takahashi K, Ichisaka T, Aoi T,
Kanagawa O, Nakagawa M, Okita K and Yamanaka S: Suppression of
induced pluripotent stem cell generation by the p53-p21 pathway.
Nature. 460:1131–1135. 2009. View Article : Google Scholar
|
|
39
|
Marión RM, Strati K, Li H, Murga M, Blanco
R, Ortega S, Fernandez-Capetillo O, Serrano M and Blasco MA: A
p53-mediated DNA damage response limits reprogramming to ensure iPS
cell genomic integrity. Nature. 460:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grinstein E and Wernet P: Cellular
signaling in normal and cancerous stem cells. Cell Signal.
19:2428–2433. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koziol MJ, Garrett N and Gurdon JB: Tpt1
activates transcription of oct4 and nanog in transplanted somatic
nuclei. Curr Biol. 17:801–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ligon KL, Huillard E, Mehta S, Kesari S,
Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, et al:
Olig2-regulated lineage-restricted pathway controls replication
competence in neural stem cells and malignant glioma. Neuron.
53:503–517. 2007. View Article : Google Scholar : PubMed/NCBI
|
